Published: 12:45, June 15, 2025
InvestHK to showcase Hong Kong’s biotech edge in US
By Wang Zhan
In this undated file photo, Andy Wong Wai-cheuk, head of Innovation and Technology at InvestHK, speaks during an interview. (PHOTO / HKSAR GOVERNMENT)

HONG KONG  – Invest Hong Kong (InvestHK) will lead a delegation on Monday to showcase the city’s unrivalled advantages and opportunities as a global biotech hub during a major international convention in the United States.  

InvestHK—the SAR government agency tasked with promoting direct investment-- and the Hong Kong Science and Technology Parks Corporation (HKSTP) will lead a delegation of 16 life science and health technology companies to the BIO International Convention 2025 in Boston to promote Hong Kong's strategic strengths as a biotech powerhouse.

It will also highlight the city's cutting-edge biotech ecosystem, which is tailored to empower American biotech firms to thrive in Asia's fast-growing markets.

InvestHK Head of Innovation & Technology Andy Wong Wai-cheuk said he will engage with local biotech stakeholders, start-ups, investors and media to attract more business and investment to Hong Kong.

The convention, running from June 16-19, will unite over 20,000 global leaders of the biotech industry, representing virtually the entire biotech ecosystem.

ALSO READ: InvestHK promotes Hong Kong's role as global financial hub in Canada

At the Hong Kong pavilion, the delegation will showcase Hong Kong's advantages and opportunities for US biotech companies seeking to expand into the Guangdong-Hong Kong-Macao Greater Bay Area and Asia-Pacific.

This undated photo shows Associate Director-General of Investment Promotion at Invest Hong Kong (InvestHK) Charles Ng Siong-kwong. (PHOTO / HKSAR GOVERNMENT) 

“Hong Kong, as a global biotech hub and one of the world's leading fundraising hubs for life science and biotech, offers unique advantages for American biotechnology companies,” Charles Ng Siong-kwong, associate director-general of investment promotion at InvestHK, said in a statement on Sunday.

These advantages included a top-tier academic research and talent pool, world-class research and development infrastructure, financial strength, robust intellectual property protection, high-quality clinical trial data and strong government commitment, Ng said, adding that all these made Hong Kong an ideal location for establishing a regional headquarters to expand into the GBA and Asia-Pacific region.

In the same statement, HKSTP’s Chief Executive Officer Albert Wong Hak-keung said that the trip aims not just to seek immediate investment but also to build long-term bridges between innovation ecosystems, offering a globally connected environment to exchange ideas, collaborate and scale.

“I expect the delegation will begin to see tangible results within the next 12 to 18 months,” Wong said.

READ MORE: InvestHK: HK a trusted gateway for global capital seeking opportunities

InvestHK said it has seen a strong momentum in attracting innovation and technology (I&T) companies to establish or expand their presence in the city. In 2024, the number of I&T companies assisted by InvestHK rose to 120, up from 82 in 2023, making it the top-performing sector among all sectors supported by the department.